Industry Voices

A few months ago, Gary Miller, Ph.D., gave a commencement speech to the University of Florida's graduating engineers. It was a fitting honor for a man who has dedicated decades to the field of engineering and was on the verge of a new chapter himself....

Jean-Paul Burtin was attracted to orthopedics by its possibility for innovation. The enticement did not disappoint.

The oversubscribed $12.5 million Series D round sets Catalyst to expand product lines and build out its infrastructure to support growth.

While autologous live cell therapies are not new, Royal Biologics is creating a unique value proposition through its growing ALC portfolio.

Technology updates, the competitive landscape and surgeon and patient interest are pushing orthopedic companies to speed robotic iterations and innovations.

The differences between the hospital and ASC setting are vast and present a learning curve for those managing, operating in and selling to outpatient centers. However, the growth opportunity connected to ASCs is significant for those companies that examine the big picture and build foundational relationships.